Liver News and Research

RSS

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.

11 Jun 2015

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

In preliminary experiments with mice and lab-grown cells, Johns Hopkins Kimmel Cancer Center scientists have found that a protein-signaling process accelerates the work of the gene most frequently mutated in a common form of adult leukemia and is likely necessary to bring about the full-blown disease.

11 Jun 2015

Percentage of female authorship in gastroenterology journals remains lower than expected

The percentage of U.S. female physician authors of original research in major gastroenterology journals has grown over time, yet the percentage of women in the senior author position remains lower than expected based on the proportion of female gastroenterologists in academia.

11 Jun 2015

Surgeons perform breakthrough operation to separate six-month-old conjoined Haitian twins

On Friday, May 22, an 18-member team of physicians and nurses from Children's Hospital Los Angeles (CHLA) and Keck Medicine of the University of Southern California (USC) led an international collaboration to separate a pair of six-month-old conjoined Haitian twins, the first such operation ever performed on Haitian soil.

11 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan.

10 Jun 2015

New microfluidic chip could save millions of euros in drug development costs

Scientists in an EU-supported project have developed a microfluidic chip that simultaneously analyses the reactions of several human organ tissues when they come into contact with candidates for new drugs.

10 Jun 2015

GSU scientists design new MRI technique for early detection of liver tumors

Scientists at Georgia State University with funding from the National Institute of Biomedical Imaging and Bioengineering have designed an imaging technique to detect early-stage liver tumors, and have proven it successful in mice.

10 Jun 2015

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Simple steps that include the consistent use of experienced medical teams for a single type of surgery, preemptive antibiotics before the procedure, less reliance on potent opioids during recovery and urging patients to get out of bed and move around sooner can not only prevent infections, blood clots and other serious complications in people undergoing colorectal operations, but can also accelerate recovery and reduce cost of care, according to results of an ongoing program at The Johns Hopkins Hospital.

10 Jun 2015

Daily sugar-sweetened beverage habit may increase NAFLD risk

A daily sugar-sweetened beverage habit may increase the risk for non-alcoholic fatty liver disease (NAFLD), researchers from the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HRNCA) at Tufts University report today in the Journal of Hepatology.

8 Jun 2015

Physicians at UH Case Medical Center implant revolutionary device to treat right ventricular heart disease

University Hospitals Case Medical Center physicians in the Harrington Heart & Vascular Institute were the first in the state of Ohio to implant a revolutionary device to treat right ventricular heart disease.

5 Jun 2015

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

The All Wales Medicines Strategy Group has recommended Daklinza (daclatasvir) for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. The recommendation is specifically for patients with advanced liver disease, for whom treatment options can be limited.

5 Jun 2015

Medical experts call for accurate, standardized estrogen testing methods

Unreliable estrogen measurements have had a negative impact on the treatment of and research into many hormone-related cancers and chronic conditions. To improve patient care, a panel of medical experts has called for accurate, standardized estrogen testing methods in a statement published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Jun 2015

Exalenz Bioscience initiates BreathID clinical study to detect primary liver cancer

Exalenz Bioscience, a leader in developing and marketing non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study designed to investigate its BreathID test to non-invasively detect primary liver cancer, also known as Hepatocellular Carcinoma (HCC).

4 Jun 2015

Study: Intravenous nutrition source may significantly reduce toxicity of platinum-based cancer drugs

A single dose of an FDA-approved intravenous nutrition source may be able to significantly reduce the toxicity and increase the bioavailability of platinum-based cancer drugs, according to a study by Carnegie Mellon University biologists published in Scientific Reports.

3 Jun 2015

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157.

3 Jun 2015

WHO accepts Elafibranor as generic name for GENFIT’s GFT505 drug candidate

GENFIT, a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces that the World Health Organization (WHO) has accepted the international non-proprietary name (INN, or generic name) Elafibranor for its leading drug candidate previously referred to as GFT505.

3 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Foundation Medicine, Inc. today presented new data including promising clinical outcomes underscoring the importance of integrating comprehensive genomic profiling with FoundationOne® into clinical oncology care for the treatment of biliary tract cancers.

2 Jun 2015

Liver News and Research

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Protein-signaling process accelerates work of gene mutation linked to common form of adult leukemia

Percentage of female authorship in gastroenterology journals remains lower than expected

Surgeons perform breakthrough operation to separate six-month-old conjoined Haitian twins

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

New microfluidic chip could save millions of euros in drug development costs

GSU scientists design new MRI technique for early detection of liver tumors

Simple steps help accelerate recovery, reduce cost of care in people undergoing colorectal surgery

Daily sugar-sweetened beverage habit may increase NAFLD risk

Physicians at UH Case Medical Center implant revolutionary device to treat right ventricular heart disease

AWMSG recommends Daklinza (daclatasvir) for treatment of adult patients with chronic HCV infection

Medical experts call for accurate, standardized estrogen testing methods

Exalenz Bioscience initiates BreathID clinical study to detect primary liver cancer

Study: Intravenous nutrition source may significantly reduce toxicity of platinum-based cancer drugs

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

WHO accepts Elafibranor as generic name for GENFIT’s GFT505 drug candidate

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News